On Friday, Zydus Cadila announced that it has received approval from Mexican regulatory authority, COFEPRIS, to conduct clinical trials with its biological therapy, Pegylated Interferon alpha-2b, 'PegiHepTM'. The trials are scheduled to begin in July 2020. They will be open-label, randomized ad comparator-controlled to evaluate safety, efficacy and tolerability in patients with COVID-19.